The Ozempic Family Tree: Every GLP-1 Drug, Explained, and What It Means for Dinner

"Ozempic" has become the word everyone uses, but it is one name in a family of roughly fourteen brands built on seven molecules. About one in eight American adults now takes one of them, and the country's restaurants are already feeling it.

A Lizard in the Bronx

The story of the most talked-about drug in America does not begin in a lab in Denmark or Indianapolis. It begins with a venomous lizard from the Arizona desert, and a doctor at the Veterans Affairs hospital in the Bronx.

The Gila monster is a slow, beaded, orange-and-black reptile that can eat only a few times a year. Between meals it goes months without food, yet its blood sugar stays steady. In the early 1990s, endocrinologist (a hormone specialist) Dr. John Eng was curious about exactly that. He ordered dried venom samples from a Utah serpentarium (a facility that keeps venomous reptiles) and started taking them apart molecule by molecule. A colleague, gastroenterologist (a digestive-system doctor) Dr. Jean-Pierre Raufman, shuttled test tubes between Brooklyn and the Bronx lab in his own car. (Military.com)

In 1992 the team described a peptide (a tiny protein, just a short chain of building blocks) nobody had seen before. They called it exendin-4.

What made it exciting was a resemblance. Exendin-4 looked and behaved a lot like GLP-1, a human gut hormone that scientists, including biochemist Svetlana Mojsov, had pinned down in the 1980s as a key trigger for insulin (the hormone that moves sugar out of the blood and into cells) after a meal. GLP-1 had one fatal flaw as a medicine: the body breaks it down in about two minutes. The lizard's version lasted for hours. (National Institute on Aging, University of Queensland)

Big drug companies were not eager to sell a hormone copied from a venomous lizard. Eng eventually found a partner in a small start-up, Amylin Pharmaceuticals. In 2005 the FDA (the US Food and Drug Administration, which decides which medicines can be sold) approved a synthetic version of exendin-4, exenatide, under the brand name Byetta. It was a twice-daily injection for type 2 diabetes (the common, adult form of diabetes, where the body stops handling sugar well), and it was the first GLP-1 drug. Everything that followed, Ozempic included, descends from that desert reptile.

What the Hormone Actually Does

Every time you eat, cells in your small intestine release a small burst of GLP-1 (glucagon-like peptide-1). It is part of the body's own "I've been fed" messaging system, and it does three things that matter at the dinner table.

It tells the pancreas (the organ tucked behind the stomach that makes insulin) to release insulin, but only when blood sugar is high. That built-in brake is why the drugs were first developed for type 2 diabetes.
It slows the stomach. Food leaves the stomach more slowly, so a meal keeps you full longer.
It talks to the brain. GLP-1 signals reach the appetite centers, turning down hunger and, for many people, the "food noise" of constant cravings.

The drugs are engineered versions of that signal, built to last a day or a week instead of two minutes. The practical effect is simple: people feel full sooner and stay full longer. In trials, the strongest of them help people lose around 15 to 20 percent of their body weight.

Newer drugs add a second hormone. Tirzepatide (Mounjaro and Zepbound) also mimics GIP, another gut hormone released after meals. Drugs in the pipeline go further, stacking a third signal or pairing GLP-1 with amylin, a satiety ("I'm full") hormone from the pancreas. The family keeps branching.

The Family Tree

Twenty-one years after Byetta, the US family counts seven molecules. Two companies dominate it: Denmark's Novo Nordisk and Indianapolis-based Eli Lilly. Here is every brand, grouped by the molecule inside. (The molecule is the active ingredient; the brand is just the name on the box.)

Brand	Molecule	Maker	Form	Approved for	First US approval
Ozempic	semaglutide	Novo Nordisk	weekly injection	type 2 diabetes	2017
Wegovy	semaglutide	Novo Nordisk	weekly injection	weight management	2021
Wegovy pill	semaglutide	Novo Nordisk	daily tablet	weight management	Dec 2025
Ozempic pill (formerly Rybelsus)	semaglutide	Novo Nordisk	daily tablet	type 2 diabetes	2019 as Rybelsus; renamed May 2026
Mounjaro	tirzepatide	Eli Lilly	weekly injection	type 2 diabetes	2022
Zepbound	tirzepatide	Eli Lilly	weekly injection	weight management, sleep apnea (breathing that stops and starts during sleep)	2023
Foundayo	orforglipron	Eli Lilly	daily tablet	weight management	Apr 2026
Victoza	liraglutide	Novo Nordisk (generics now too)	daily injection	type 2 diabetes	2010
Saxenda	liraglutide	Novo Nordisk	daily injection	weight management	2014
Trulicity	dulaglutide	Eli Lilly	weekly injection	type 2 diabetes	2014
Byetta	exenatide	originally Amylin	twice-daily injection	type 2 diabetes	2005 (US supply discontinued)
Bydureon BCise	exenatide	AstraZeneca	weekly injection	type 2 diabetes	2012 (US supply discontinued)
Adlyxin	lixisenatide	Sanofi	daily injection	type 2 diabetes	2016 (withdrawn)

Two more products hide GLP-1 inside an insulin pen: Soliqua (lixisenatide with insulin glargine) and Xultophy (liraglutide with insulin degludec). And the older molecules now have generics (cheaper copies other companies can sell once the patent runs out): Teva and Hikma sell generic liraglutide, and Amneal sells generic exenatide. (Modern Weight Science, WeightLossRankings)

Only a handful carry an official weight-loss label: Wegovy (injection and pill), Zepbound, Foundayo and Saxenda. Everything else is, on paper, a diabetes drug.

Why One Drug Has Five Names

Semaglutide alone has worn five brand names in the US: Ozempic, Wegovy, Rybelsus, the Wegovy pill and the Ozempic pill. The logic is regulatory, not chemical. The FDA approves a drug for a specific use at a specific dose, and companies give each approval its own brand.

So Ozempic and Wegovy contain the same molecule. Ozempic is labeled for type 2 diabetes. Wegovy comes in higher doses and is labeled for weight loss, which is why a doctor prescribing Ozempic for weight loss is technically prescribing it off-label (for a use not listed on its official label, which is legal and common). The same split repeats at Lilly: Mounjaro for diabetes, Zepbound for weight.

Then culture rewrote the map. "Ozempic" became the word people use for the whole category, the way Kleenex stands in for tissues. Novo Nordisk leaned in. In May 2026 it retired the Rybelsus name in the US and relaunched its reformulated diabetes tablet as the Ozempic pill, at new 1.5, 4 and 9 mg strengths. Rybelsus, approved in 2019, had been the first GLP-1 in pill form, but the famous name was simply better marketing. (Fierce Pharma, Pharmacy Times)

So, how many are there?

It depends on how you count, which is why different guides give different answers.

Molecules: seven (semaglutide, tirzepatide, orforglipron, liraglutide, dulaglutide, exenatide, lixisenatide).
Brands ever approved in the US: about fourteen, counting Rybelsus and the pills.
Brands most people can actually get today: about ten to eleven, since Byetta, Bydureon and Adlyxin have left the market and Rybelsus is being phased into the Ozempic pill.
Pills: three, all new or renamed in the past year: the Wegovy pill, the Ozempic pill and Foundayo.

The pills are the real story of 2026. The Wegovy pill, approved in December 2025, was the first GLP-1 tablet for weight loss. It has to be taken on an empty stomach with little water. Lilly's Foundayo, approved April 1, 2026, is the first non-peptide GLP-1: a small molecule (a simple chemical compound, like most everyday pills, instead of a protein-like peptide that stomach acid breaks down) that can be taken any time of day, with or without food. The FDA cleared it 50 days after filing, its fastest approval of a new molecule since 2002. (Novo Nordisk, FDA)

Pills are cheaper to make and easier to take than injections, so they are expected to widen the circle of users. J.P. Morgan has estimated that US GLP-1 users could grow from about 10 million in 2026 to more than 30 million by 2030. (CNBC)

The Next Wave

The family tree is still growing, and the next branches stack hormones on top of each other.

CagriSema (Novo Nordisk). A weekly shot combining semaglutide with cagrilintide, a long-acting version of amylin, the hormone that tells your brain you are full. In its main trial, people lost about 20 percent of their body weight over 68 weeks. Novo filed it with the FDA in December 2025, and a decision is expected in late 2026. (Novo Nordisk, PharmExec)
Retatrutide (Eli Lilly). A "triple agonist": one drug that switches on three hormone signals at once, GLP-1, GIP and glucagon. (Think of receptors as locks on the surface of cells, and these drugs as keys that fit them.) Several of its late-stage trials wrapped up in 2026. (ClinicalTrials.gov)
A 25 mg Ozempic pill. A stronger dose of the diabetes tablet, with an FDA decision expected in the fourth quarter of 2026. (Novo Nordisk Q2 2026 report)
More in the pipeline. Amgen's MariTide, plus survodutide, mazdutide and others, each testing a different hormone combination or dosing schedule.

There is also a gray branch: compounded semaglutide and tirzepatide, mixed by pharmacies and sold cheaply online. They are not FDA-approved, and quality varies from pharmacy to pharmacy.

The direction is clear. Each generation hits more targets, works more strongly, or comes in an easier form. Whatever the effect on waistlines, the effect on how America eats is only getting bigger.

What It Means at the Table

GLP-1 users still eat out. They just order differently, and restaurants have noticed.

The spending data

The clearest numbers come from Cornell University researchers who tracked real purchases, not surveys, from a panel of about 150,000 US households. Within six months of someone starting a GLP-1 drug, the household cut grocery spending by 5.3 percent on average, and by more than 8 percent in higher-income homes. Spending at fast-food chains, coffee shops and other counter-service spots fell by about 8 percent. Savory snacks took the biggest hit, down about 10 percent. (Cornell Chronicle)

How to read it: this is the most reliable number in the debate, because it tracks what people actually paid, before and after starting the drug. The cuts land where cravings live: chips, sweets, the drive-through, the afternoon latte. Notice also that the whole household spends less, not just the person on the medication.

But sit-down dining tells a more interesting story.

Same number of dishes, different dishes. Market researcher Circana found GLP-1 users cut items ordered per restaurant visit by only 1 percent, but chose more mains and fewer sides. (Fox News) How to read it: the plate that suffers is the extra one, the fries or the shared appetizer nobody really needed, not the main course.
Users dine out more often, but not because of the drug. A 2026 National Restaurant Association survey found GLP-1 users bought a meal, snack or drink from a restaurant 7.6 times in the previous week, versus 5.1 times for non-users. (National Restaurant Association) How to read it: a coffee counts the same as a dinner, and the answers are self-reported. More importantly, these drugs are expensive, so users skew toward higher-income people who already eat out a lot. The survey shows who takes GLP-1s, not what the drugs do. Put it next to Cornell's receipts and the picture is: frequent diners who, once on the drug, spend a bit less each time.
They plan to eat lighter, and drink less. A BCG survey of more than 1,500 users found they plan to order smaller portions, choose lighter dishes and drink less alcohol when they go out. (BCG) How to read it: these are intentions, not receipts, but they point the same way as the hard data. The lost revenue sits in portion size and the bar tab, not in empty seats.

The bottom line: GLP-1s are not emptying dining rooms. They hit snacking and grab-and-go hardest, and at a sit-down meal they shrink the check around the edges: one less side, a smaller portion, a skipped second drink. For a restaurant, the question is less "will they come?" and more "what will they order when they do?"

The menus

Chains moved first. Shake Shack launched a "Good Fit" menu with lettuce-wrapped burgers. Chipotle added high-protein cups that are essentially small bowls of meat. Smoothie King labeled a section of its menu for GLP-1 users. (Tasting Table) Even Olive Garden and The Cheesecake Factory, famous for oversized plates, now sell smaller, cheaper portions. (Fortune/AP)

New York has its own examples. Clinton Hall sells a "Teeny Weeny Mini Meal" of a mini burger, mini fries and a mini beer. (CNBC) Cuba Libre Restaurant & Rum Bar, which operates up and down the East Coast, introduced a dedicated GLP-1 menu. Its co-founder argues this is a lasting shift in how people eat, not a fad. (WBUR)

Not everyone is on board. Gordon Ramsay called GLP-1 menus embarrassing, arguing that eating out is supposed to be a celebration, not a calorie exercise. (Fox News) It is a fair question for any restaurant: is the job to feed people, or to give them an evening?

The bar

The quieter effect may be on drinks. GLP-1 drugs appear to dampen alcohol cravings as well as food cravings. A randomized trial (a study where people are assigned by chance to get either the drug or a placebo, a dummy pill) published in The Lancet in May 2026 found that semaglutide cut heavy drinking more than placebo in adults with obesity and alcohol use disorder (the medical term for problem drinking). (Forbes)

For restaurants, that matters because drinks carry the best margins (the most profit on each dollar sold). The industry response so far: more zero-proof (alcohol-free) cocktails, lower-alcohol options, smoothies and wellness drinks. (Fox News) The second round of cocktails may be the real casualty of the Ozempic era, more than the entree.

Small Plates, Old Idea

For American chains, "GLP-1 friendly" means inventing something new: the half portion, the protein cup, the mini meal. For much of the world's cooking, the idea is centuries old.

A Korean meal arrives as a spread of banchan, small side dishes that everyone picks from. A Mediterranean table starts with meze: a few dips, a salad, grilled vegetables, a plate of something from the sea. Spain has tapas, Japan has izakaya plates, Italy has cicchetti in Venice's bars. None of these were designed around appetite suppressants. They were designed around company. You order a table's worth, you share, and each person eats as much or as little as they want without anyone counting.

That format happens to answer almost every GLP-1 complaint at once. Nobody is stuck with a 1,500-calorie entree they cannot finish. Protein and vegetables sit next to each other on the table. The diner who eats less still gets the full evening: the conversation, the tasting, the ritual. It is the answer to Gordon Ramsay's objection, too. A shared table keeps the celebration and loses the obligation to clean a giant plate.

It is also a quiet argument for the kind of restaurants that fill blocks like Ninth Avenue in Hell's Kitchen: small, independent kitchens cooking from cuisines where sharing was always the point. The chains are retrofitting their menus. Those kitchens were already built for how a growing slice of America wants to eat.

A Note, and Sources

This article is about food culture and the restaurant business, not medical advice. Whether any of these drugs is right for someone, and which one, is a conversation for that person and their doctor.

Approval dates and pipeline status reflect public reports as of late September 2026 and change quickly.

The 47th Bite

Search This Blog